Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus by M. Gerosa et al.
February 2016 | Volume 7 | Article 51
PersPective
published: 01 February 2016
doi: 10.3389/fimmu.2016.00005
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Kenneth Michael Pollard, 
The Scripps Research Institute, USA
Reviewed by: 
Wenxia Song, 
University of Maryland, USA 
David M. Cauvi, 
University of California San Diego, 
USA
*Correspondence:
Pier Luigi Meroni  
pierluigi.meroni@unimi.it
Specialty section: 
This article was submitted to 
B Cell Biology, 






Gerosa M, Poletti B, Pregnolato F, 
Castellino G, Lafronza A, Silani V, 
Riboldi P, Meroni PL and Merrill JT 
(2016) Antiglutamate Receptor 
Antibodies and Cognitive Impairment 
in Primary Antiphospholipid 
Syndrome and Systemic Lupus 
Erythematosus. 
Front. Immunol. 7:5. 
doi: 10.3389/fimmu.2016.00005
Antiglutamate receptor Antibodies 
and cognitive impairment in Primary 
Antiphospholipid syndrome and 
systemic Lupus erythematosus
Maria Gerosa1,2 , Barbara Poletti3 , Francesca Pregnolato4 , Gabriella Castellino5 , Annalisa 
Lafronza3 , Vincenzo Silani3,6 , Piersandro Riboldi1,5 , Pier Luigi Meroni1,4* and Joan T. Merrill7
1 Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 2 Division of Rheumatology, Lupus 
Clinic, Istituto Ortopedico Gaetano Pini, Milan, Italy, 3 Department of Neurology-Stroke Unit and Laboratory of Neuroscience, 
IRCCS Istituto Auxologico Italiano, Milan, Italy, 4 Experimental Laboratory of Immunological and Rheumatologic Researches, 
IRCCS Istituto Auxologico Italiano, Milan, Italy, 5 Allergy, Clinical Immunology and Rheumatology Unit, IRCCS Istituto 
Auxologico Italiano, Milan, Italy, 6 Department of Pathophysiology and Transplantation, “Dino Ferrari” Center, Università degli 
Studi di Milano, Milan, Italy, 7 Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, University 
of Oklahoma, Oklahoma City, OK, USA
Systemic lupus erythematosus (SLE) and antiphospholipid syndrome have an increased risk 
to develop cognitive impairment. A possible role for antiphospholipid antibodies (aPL) and 
antiglutamate receptor (anti-NMDA) antibodies in the pathogenesis of neurological manifes-
tations of these two conditions, have been suggested. In particular, the role of anti-NMDA 
antibodies in the pathogenesis of neuropsychiatric SLE is supported by several experimental 
studies in animal models and by the finding of a correlation between anti-NMDA positivity in 
cerebrospinal fluid and neurological manifestations of SLE. However, data from the literature 
are controversial, as several studies have reported a correlation of these antibodies with mild 
cognitive impairment in SLE, but more recent studies have not confirmed this finding. The 
synergism between anti-NMDA and other concomitant autoantibodies, such as aPL, can 
be hypothesized to play a role in inducing the tissue damage and eventually the functional 
abnormalities. In line with this hypothesis, we have found a high incidence of at least one 
impaired cognitive domain in a small cohort of patients with primary APS (PAPS) and SLE. 
Interestingly, aPL were associated with low scoring for language ability and attention while 
anti-NMDA titers and mini-mental state examination scoring were inversely correlated. 
However, when patients were stratified according to the presence/absence of aPL, the cor-
relation was confirmed in aPL positive patients only. Should those findings be confirmed, the 
etiology of the prevalent defects found in PAPS patients as well as the synergism between 
aPL and anti-NMDA antibodies would need to be explored.
Keywords: systemic lupus erythematosus, antiphospholipid syndrome, mild cognitive impairment, 
neuropsychological assessment, central nervous system involvement, anti-NMDA/glutamate receptor antibodies
Abbreviations: ANA, antinuclear antibodies; anti-CL, anticardiolipin; anti-dsDNA, antidouble strand DNA; anti-PL, antiphos-
pholipid antibodies; anti-β2GPI, anti-β2 glycoprotein I; APS, antiphospholipid syndrome; BBB, blood–brain barrier; CCI, 
cognitive impairment index; CNS, central nervous system; CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent 
assay; ENA, extractable nuclear antigen; ICV, intracerebroventricular; Ig, immunoglobulins; LA, lupus anticoagulant; MMSE, 
mini-mental state examination; NMDA, human glutamate receptor; NPSLE, neuropsychiatric SLE; PAPS, primary APS; SLE, 
systemic lupus erythematosus.
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iNtrODUctiON
Systemic lupus erythematosus (SLE) is a chronic disease charac-
terized by antibodies directed to different components of the cell 
nucleus in association with a variety of clinical manifestations, 
including skin rash, arthritis, serositis, nephritis, hematological 
cytopenias, and neurological manifestations. The prevalence 
ranges from 15 to 50 cases per 100,000 persons and the inci-
dence is around 2–8 new cases per 100,000 persons per year. 
Polyclonal B-cell stimulation and autoantibody production, 
leading to immune complex deposition and complement activa-
tion represent the most important pathogenic mechanisms of 
the disease (1). Treatment of SLE largely depends on the type of 
clinical manifestations: antimalarial agents in association with 
low-dose steroids represent the first choice in mild disease, while 
immunosuppressant agents, such as azathioprine, methotrexate, 
cyclophosphamide, and mycophenolate mofetil are used in more 
severe manifestations. Recently, belimumab, a new biological 
agent able to modulate B lymphocyte function, has been demon-
strated to reduce lupus disease activity (1).
Antiphospholipid syndrome (APS) is a systemic autoimmune 
disease close to SLE with significant overlap of serological and 
clinical characteristics (2). It is mainly characterized by preg-
nancy complications and thrombotic events, involving both the 
venous and the arterial district (2). The formal classification of 
APS requires the persistent presence of medium to high titers 
of antiphospholipid antibodies (anti-PL), namely anti-β2 gly-
coprotein I (anti-β2GPI), anticardiolipin (anti-CL), and lupus 
anticoagulant (LA) (2). The disease can occur as an isolate 
clinical entity [primary APS (PAPS)] or associated with other 
autoimmune diseases, mainly with SLE (secondary APS). The 
prevalence is estimated around 40–50 cases per 100,000 persons 
and the incidence is around five new cases per 100,000 persons 
per year. Elevated levels of anti-PL and positivity to more than 
one test have been linked to a higher risk for developing the 
disease (3). Treatment of APS is based on prevention of recur-
rence and is mainly represented by long term anticoagulation. 
Hydroxychloroquine, statins, rituximab, and eculizumab can be 
considered in refractory cases (3).
cOGNitive iMPAirMeNt iN APs  
AND sLe
Among the several neurological symptoms related to SLE and 
classified by the American College of Rheumatology (3), cogni-
tive dysfunctions have been reported to affect 6–66% of the 
patients according to different studies, but the prevalence may be 
up to 95% when cognitive defects are assessed by computerized 
neuropsychological testing (4). This literature is confusing, and 
the real incidence of dementia or mild cognitive defects in SLE 
patients has not yet been well defined.
Neurological involvement is very frequent in APS, cerebral 
stroke being one of the most common vascular manifestations. 
In fact, ischemic events are the most frequently observed 
central nervous system (CNS) complications of PAPS and 
represent one of the formal classification criteria. Multi-infarct 
dementia is also described in these patients, mainly associated 
with recurrent ischemic events, with an incidence estimated 
as 10–56% increasing with age (3, 5, 6). Additional manifesta-
tions, such as migraine, seizures, chorea, transverse myelopathy, 
and multiple sclerosis-like syndrome have been reported (3). 
Cognitive impairment has frequently been addressed as a 
neurological APS “non-classification criterion.” However, this 
finding has usually been described in APS associated with an 
underlying systemic autoimmune disease in the majority of the 
reports, mainly in SLE-associated APS, while only two studies 
are available in the literature in PAPS (5, 6). A case–control 
study of 60 patients with primary or secondary APS found 
that 42% presented mild cognitive defects, primarily involving 
verbal fluency and attention. Looking at PAPS patients only, the 
prevalence was about the same (38%); however, besides anti-PL, 
no further correlation with serological profiles was evaluated 
(5). Similar results have recently been reported in a study 
comparing the cognitive function of anti-PL positive non-SLE 
subjects and anti-PL negative SLE patients (6). In this study, 20 
SLE anti-PL negative patients and 20 anti-PL positive subjects, 
with or without clinical manifestations of APS, were investigated 
through a standardized cognitive test battery; 60% of SLE and 
40% of anti-PL positive subjects displayed a cognitive impair-
ment assessed by a global cognitive impairment index (CCI). 
This finding was not associated to disease activity or duration, 
while a possible correlation with the whole serological profile 
was not assessed (6).
Cognitive defects in PAPS cannot be simply explained by 
ischemic events; therefore, a direct effect of anti-PL on neuronal 
cells was suggested. Accordingly, anti-PL were found to bind 
CNS cells in vitro (7) and the intrathecal passive transfer of class 
G immunoglobulins (IgG) from APS patients were shown to 
induce cognitive defects in mice in vivo (7). These results have 
been recently confirmed by the same group, which demonstrated 
that the intracerebroventricular (ICV) passive transfer of human 
anti-PL IgG  purified from the serum of APS patients with CNS 
involvement induced specific hyperactivity in injected mice (7). 
In addition to anti-PL, PAPS patients can display several organ 
non-specific autoantibodies, such as ANA, anti-dsDNA, antinu-
cleosome, and anti-extractable nuclear antigen (anti-ENA), even 
in the absence of evident clinical manifestations of SLE (3).
Lupus-specific mechanisms underlying neuropsychiatric 
disease are better known and have been related to vasculitides 
of intracranial vessels, local or systemic production of inflam-
matory mediators, and generation of specific autoantibodies (8). 
Different types of autoantibodies have been investigated, such 
as aPL themselves and antiribosomal P protein antibodies (4, 8, 
9). An increasing interest has been raised during the last decade 
for antibodies reacting to the human glutamate receptor (anti-
NMDA) as potentially involved in the pathogenesis of neurologi-
cal manifestations of SLE.
ANti-NMDA ANtiBODies
A murine monoclonal anti-DNA antibody has been recently 
shown to cross-react with the extracellular domain of mouse 
and human glutamate receptor (NMDA) and to induce cogni-
tive dysfunction in mice through neuronal cell apoptosis (10). 
FiGUre 1 | correlation between MMse score and anti-NMDA antibody titer in the whole population (A), aPL negative patients (B), and aPL positive 
patients (c), only. Spearman’s rho coefficient and relative p-value are reported on the top right corner of the graph. Curves are fitted according to a second 
polynomial equation model.
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Affinity-purified anti-NMDA antibodies were demonstrated to 
induce apoptotic cell death in  vitro, when added to neuronal 
cultures. Moreover, mice immunized with a specific antigen to 
produce anti-NMDA antibodies developed cognitive dysfunc-
tion and spatial memory impairment only when a blood–brain 
barrier (BBB) disruption occurred (10). The autoantibodies 
selectively bound to hippocampal neurons and caused neuronal 
death. Interestingly, the administration of memantine, an NMDA 
receptor antagonist, prior to BBB disruption, prevented neuronal 
damage (10). Moreover, the direct injection of antibodies eluted 
from the brain of a SLE patient with severe CNS involvement in 
the C57BL/6 mice hippocampus was able to induce neuronal loss 
(10). More recently, the same group has demonstrated that anti-
NMDA antibodies development was associated with selective 
impairment of spatial memory in female BALB/c mice and that 
relevant structural abnormalities could be observed in the surviv-
ing hippocampal pyramidal neurons (11). Further investigations 
have shown the presence of similar anti-NMDA antibodies in 
both serum and cerebrospinal fluid (CSF) of SLE patients even 
if a clear clinical association between these autoantibodies and 
cognitive defects has not yet been established (12).
Anti-NMDA antibodies have been reported in SLE patients 
with a prevalence of 19–33% in different studies (4, 9). Given 
their  high pathogenicity of these in experimental animal models, 
a possible relationship with neuropsychiatric manifestations of 
SLE was investigated. Some authors have reported an association 
between anti-NMDA and several neurological manifestations, 
such as cognitive impairment, decline in memory functions, 
impaired attention or executive functions, and depression. 
However, some other studies in very large cohorts of lupus 
patients have not confirmed these data (4, 9). Remarkably, an 
association between the presence of anti-NMDA in the CSF and 
NP-SLE (neuropsychiatric SLE) manifestations was demonstrated 
in different studies. Moreover, CSF anti-NMDA titers correlated 
with clinical manifestations and with evidence of BBB dysfunc-
tion (11). Data examining the PAPS population for anti-NMDA 
are scant. No correlation between the presence of anti-NMDA 
and anti-CL in a SLE population was previously found, but these 
autoantibodies have not been evaluated in selected cohorts of 
primary APS patients (4).
With this as a background, we have recently examined the 
incidence of cognitive dysfunctions in a cohort of consecutive 




• Anti-NMDA ab from SLE pts cross-react with anti-dsDNA DeGiorgio et al. (13), Kowal 
et al. (14), Kowal et al. (10), 
Chang et al. (11)
• Affinity-purified anti-NMDA ab added to neuronal cultures induce apoptotic cell death
• Anti-NMDA/dsDNA cross-reactive ab induce “excitotoxicity” and neuronal apoptosis
Humans • Anti-NMDA ab have been detected in 14–35% of SLE patientsa–f a. Omdal et al. (15)
b. Lapteva et al. (16)
c. Harrison et al. (17)
d. Hanly et al. (9)
e. Kozora et al. (18)
f. Husebye et al. (19) 
g. Gono et al. (20)
h. Hanly et al. (21)
i. Arinuma et al. (22)
j. Yoshio et al. (23) 
k. Hirohata et al. (12)
l. Chang et al. (11)
• No correlation between the presence of anti-NMDA and anti-CL in a SLE populationf
• Some authors have reported an association between anti-NMDA and
  Cognitive impairmenta
  Decline in memory functionsa
  Impaired attention or executive functionsa
  Depressiona,b
  NPSLEg
• Recent studies in very large cohorts of lupus patients have reported NO association between anti-NMDA with
  Cognitive impairmentb–d,h
  Epilepsyi
  Mood disordersc,d
• Several studies have demonstrated an association between the presence of anti-NMDA in the CSF and NPSLEh–l
• CSF anti-NMDA titers correlated with clinical manifestations and with evidence of BBB dysfunctionh–l
Our results • 27 SLE and 15 PAPS underwent an extensive neuropsychological text battery
• 44% SLE and 33% PAPS anti-NMDA ab positive (no differences in prevalence and titer)
• 70% SLE and 86% PAPS exhibited at least 1 defective domain
• 11% SLE and 33% PAPS exhibited 4 or more pathologic tests
• Mathematical abilities, attentional skills, and visual-motor planning were the most frequently affected cognitive domains
• PAPS patients significantly deviate from SLE patients in the Phonemic Verbal fluency and Street’s Completion Test
• Anti-PL correlate with lower scoring for language ability and attention
• High anti-NMDA IgG titers correlate with low scoring for MMSE in the whole population and in anti-PL-positive 
patients but NOT in aPL-negative patients independently from diagnosis
Animal 
models
• BALB/c mice immunization to produce anti-NMDA antibodies or
• Intravenous infusion of serum from SLE pts, containing anti-NMDA ab in 
BALB/c mice
• BBB abrogation induced by LPS
Cognitive dysfunction and spatial 
memory impairment development
DeGiorgio et al. (13),  
Kowal et al. (14)
Neuronal binding and apoptotic death 
in hippocampus
Prevention of antibody-mediated injury 
by the NMDA receptor antagonist 
memantine
• BALB/c mice immunization to produce anti-NMDA antibodiesn
• BBB abrogation induced by epinephrineo
Neuronal binding and apoptotic death 
in amygdalan
n. Kowal et al. (14) 
o. Huerta et al. (24) 
Aberrant pavlonian fear conditioningo
• Direct injection of ab eluted from the brain of a severe NPSLE patient in the 
C57BL/6 mice hippocampus
ab-mediated neuronal damage Kowal et al. (10)
Ab, antibodies; pts, patients; BBB, blood–brain barrier; LPS, lipopolysaccharide; NPSLE, neuropsychiatric SLE; CSF, cerebrospinal fluid; MMSE, mini-mental state examination.
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unselected PAPS in order to compare the results with those 
found in a parallel series of SLE patients and to better character-
ize the pattern of cognitive involvement in these two diseases 
and the possible associations between cognitive defects and 
the autoantibody profile. The protocol was approved by the 
Institutional Review Board (IRB) and informed consent was 
obtained from all the participants. Forty-two patients, 15 with 
a diagnosis of PAPS and 27 with a diagnosis of SLE, regularly 
followed in our Unit, underwent a 180 min neuropsychological 
test battery. Anti-NMDA levels were detected by a home-made 
enzyme-linked immunosorbent assay (ELISA) using a branched 
peptide as antigen (Asp Trp Glu Tyr Ser Val Trp Leu Ser Asn8 
Lys4 Lys2 Lys-β Ala) (9). Among SLE patients, all were ANA 
positive, three were positive for antiribosomal P antibodies, 13 
for anti-dsDNA antibodies at medium/high titer, eight for LA, 
three for anti-CL IgG, five for anti-β2GPI IgG, two for anti-CL 
IgM, and three for anti-β2GPI IgM at medium/high titer. Among 
PAPS patients, ANA were positive in 8 and 2 were positive for 
medium/high titer anti-dsDNA antibodies. All patients had high 
titer anti-CL IgG and 14 patients high titer anti-β2GPI IgG, while 
LA was positive in 13 patients. Anti-NMDA antibodies were 
positive in 12 SLE and 5 PAPS, with no differences in prevalence 
and titer range. Considering the whole population, the incidence 
of cognitive dysfunctions was high since 76% of the population 
(13 PAPS and 19 SLE) exhibited at least one defective domain. 
In five PAPS and three SLE patients, four or more tests were 
pathologic and mathematical abilities, attentional skills, and 
visual-motor planning were the most frequently affected cogni-
tive domains. However, when comparing score severity, PAPS 
patients significantly deviate from SLE patients in the Phonemic 
Verbal fluency (U = 121.5; p = 0.018) and Street’s Completion 
Test (U = 128.0; p = 0.043). The presence of anti-PL was found to 
correlate with lower scoring for language ability and attention. A 
correlation between high anti-NMDA IgG titers and low scoring 
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for the mini-mental state examination (MMSE) was found in 
the whole population (Rho −0.298; p = 0.037). However, when 
patients were stratified according to the presence or the absence 
of anti-PL, the correlation was maintained in anti-PL positive 
patients only (Rho – 0.396; p = 0.042) (Figure 1). Higher anti-
NMDA titers were associated with low scores for the MMSE 
test, independently from the disease diagnosis. In Table  1 are 
summarized the results of the most important studies regarding 
anti-NMDA in SLE.
cOMMeNts
Systemic lupus erythematosus patients are known to be more 
likely to develop cognitive impairment compared to the general 
population, and an association with anti-PL or anti-NMDA 
antibodies has been suggested (4, 5). Data from the literature 
are controversial, as several studies have reported a correlation 
of these antibodies with mild cognitive impairment in SLE, but 
more recent studies have not confirmed this finding. The role 
of anti-NMDA antibodies in the pathogenesis of NP-SLE is 
supported by experimental studies and by the finding of a cor-
relation between anti-NMDA positivity in CSF and neurological 
manifestations of SLE. Not all the anti-NMDA positive patients 
display a BBB interruption that can allow circulating antibodies 
to reach the CNS and induce damage. Moreover, patients with 
previous BBB damage could recover, limiting access to the brain 
for the autoantibodies, which might continue to be measured 
in the peripheral blood. In this regard, the synergism between 
anti-NMDA and other concomitant autoantibodies could 
play a role in inducing the tissue damage and eventually the 
functional abnormalities. In line with this hypothesis, we can 
speculate that one of the potential mechanisms leading to BBB 
disruption could be represented by the endothelial perturba-
tion induced by β2GPI-dependent aPL, which could possibly 
facilitate the access of anti-NMDA antibodies in the cerebral 
circulation. Nevertheless, infections, CNS inflammation, or 
other autoantibodies interaction can alternatively be implicated 
in BBB damage.
Our preliminary results are in accordance with this assump-
tion. The occurrence of anti-NMDA antibodies in PAPS patients 
is not surprising. Anti-NMDA activity was originally described in 
anti-DNA antibodies derived from SLE mice (10) and antibodies 
to nuclear antigens can be found in PAPS (3).
In conclusion, both anti-PL and anti-NMDA antibodies 
behave as promising potential biomarkers of CNS involvement 
even if further longitudinal studies are essential to define the risk 
for a potential evolution and to also clarify the opportunity of 
starting a possible preventive therapy. Due to the great impact of 
cognitive impairment on quality of life and given the cognitive 
decline which has been described even in patients with a recent 
diagnosis, we propose that SLE and PAPS patients should be 
monitored for the development of cognitive impairment.
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